Takeda Files Citizen Petition In Hopes Of Fighting Generic Competition


Velcade, Takeda’s multiple myeloma blockbuster drug, doesn’t have much patent protection left. Takeda has filed a citizen petition with the FDA in hopes of keeping any generic versions of the drug from reaching the market until February of 2018. Takeda maintains that one exclusivity period for the drug lasts until 2022. Takeda claims that several of the proposed copycat drugs use different ingredients and should undergo further testing.

Read the source article at FiercePharma

About the Author

Related Posts

Leave a Reply